Product Images Tizanidine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Tizanidine NDC 51655-603 by Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 51655 603 20 Master Bottle Label Approval Rev A 02 21

Label - 51655 603 20 Master Bottle Label Approval   Rev A 02 21

NDC 51655-603-20 is a bottle of 20 tablets of Tizanidine 4mg, a medication used to treat muscle spasms caused by certain conditions such as multiple sclerosis or spinal cord injury. The dosage should be followed as per package insert, and the tablets should be stored in a controlled room temperature between 15-30°C. It is important to keep the tablets out of children's reach and store them in the original container. The tablets should not be interchanged with Tizanidine capsules. The repackaging of the medication has been done by Northwind Pharmaceuticals. The tablet contains 4.576mg tizanidine hydrochloride USP, which is equivalent to 4mg tizanidine base. The medication has been manufactured by Dr. Reddy's Laboratories Limited. The lot number and the expiration date of the medication are not available.*

fig1 - fig1

fig1 - fig1

This text displays a chart of plasma Tzanidine concentration in ng/mL based on different dosing scenarios of 4mg Tzanidine tablets and capsules with or without food. The chart is presented over time, with hours from dosing displayed at the bottom. Additionally, the text includes a reference to a company or organization called "2500 Eoiir Mamar RAS Nemar JRes! BN BA% Rak Gar azwaa", but this is likely a result of errors and is not a useful description of the text content.*

fig2 - fig2

fig2 - fig2

fig3 - fig3

fig3 - fig3

The text is describing a study related to the improvement in Ashworth Score. The drug used in the study is Zanidine at a mean dose of 28.6 mg. The endpoints of the study were at Week 3 and End of Maintenance (Week 7). The last observation was carried forward for analysis.*

structure - structure

structure - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.